|1.||Rae, James M: 17 articles (05/2015 - 12/2003)|
|2.||Flockhart, David A: 15 articles (12/2014 - 12/2003)|
|3.||Goetz, Matthew P: 13 articles (04/2015 - 12/2005)|
|4.||Ingle, James N: 12 articles (04/2015 - 12/2005)|
|5.||Schwab, Matthias: 12 articles (08/2014 - 11/2004)|
|6.||Brauch, Hiltrud: 11 articles (08/2014 - 11/2007)|
|7.||Stearns, Vered: 11 articles (03/2012 - 12/2003)|
|8.||Ames, Matthew M: 10 articles (04/2015 - 12/2005)|
|9.||Nakamura, Yusuke: 10 articles (02/2015 - 05/2008)|
|10.||Hayes, Daniel F: 9 articles (09/2013 - 12/2003)|
|1.||Breast Neoplasms (Breast Cancer)
05/01/2015 - "Re: Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies."
02/01/2015 - "Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies."
08/10/2014 - "The numerous existing studies investigating the association of CYP2D6 with treatment failure in breast cancer are inconsistent and give rather conflicting results. "
08/01/2012 - "The aim of this study was to evaluate the relation of CYP2D6 genotyping and phenotyping with EDF levels and [NDT]/[EDF] metabolic ratio in breast cancer patients from South of Brazil under TAM therapy. "
01/01/2012 - "In samples from a breast cancer clinical trial (Trial 1), we compared the genotyping results in samples before and after WGA for three SNPs in CYP2D6, one SNP in CYP2C19, one SNP in CYP19A1, two SNPs in ESR1, and two SNPs in ESR2. "
|2.||Drug Toxicity (Drug Safety)
04/01/2009 - "Individuals who are CYP2D6 poor metabolizers, have an increased risk of adverse drug reactions (ADRs) when treated with CYP2D6-metabolized drugs, suggesting that CYP2D6 genotyping might be beneficial for patient care. "
01/01/2014 - "CYP2D6 is genetically polymorphic and is associated with large interindividual variations in therapeutic efficacy and drug toxicity. "
01/01/2015 - "In contrast to absence of the CYP2D6*4 (G1846A) and *14 (G1758A) alleles in Iranian populations of different ethnicities, the prediction of the CYP2D6*10 allele is required in drug research and routine treatment, where the information would be helpful for clinicians to optimize therapy or identify persons at risk of adverse drug reactions before clinical trials. "
01/01/2007 - "Our aim was to compare the distribution of functional polymorphisms in the genes CYP2D6 and CYP2C19 between healthy control group and of patients reffered to our department due to adverse drug reactions or insufficient efficacy of a treatment. "
01/01/2005 - "This study tested whether the CYP2D6 poor metabolizer phenotype was associated with adverse drug reactions (ADRs) and discontinuation due to ADRs. "
01/01/2013 - "To investigate the efficacy of DM as a pre-emptive analgesic agent and describe the population pharmacokinetics in the presence of normal and poor CYP2D6 metabolism in acute post-operative pain. "
10/01/2015 - "No difference in the outcome of pain across the CYP2D6 phenotypes was observed. "
10/01/2015 - "To investigate the role of CYP2D6 phenotype in the outcome of postoperative (PO) pain (POP) treatment. "
02/15/2014 - "This suggests that pain relief will vary with CYP2D6 genotype. "
01/01/2014 - "Genetic polymorphisms in CYP2D6 are associated with diminished pain relief and/or severe opioid side effects. "
|4.||Alzheimer Disease (Alzheimer's Disease)
11/01/2011 - "Individualized therapy based on CYP2D6 and BCHE genotypes is unlikely to be beneficial for treating Alzheimer's disease patients in routine clinical practice."
08/15/2014 - "Quantitative assessment of CYP2D6 polymorphisms and risk of Alzheimer's disease: a meta-analysis."
02/01/2006 - "Our results indicate that CYP2D6 polymorphism is unlikely to represent a major risk factor in susceptibility to Alzheimer's disease."
02/01/2006 - "In order to elucidate whether a relationship exists between CYP2D6 polymorphism and the risk of developing Alzheimer's disease (AD), CYP2D6 allele and genotype frequencies have been evaluated in 94 patients from Southern Italy (29 men and 65 women, aged 74+/-8 years) with AD, and in 350 healthy controls (204 men, 146 women, aged 33+/-9 years) from the same geographical region. "
02/01/2006 - "No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population."
|5.||Schizophrenia (Dementia Praecox)
09/01/2008 - "There is a lack of clinical studies of the impact of CYP2D6 polymorphism on therapeutic efficacy, especially in the long-term treatment of schizophrenia. "
12/01/2007 - "The present study shows a lower frequency of PMs in schizophrenic patients than in healthy volunteers supporting the hypothesis of a potential role of CYP2D6 in the vulnerability to schizophrenia."
11/01/2007 - "Moreover, recently we have found that CYP2D6 poor metabolizers are under-represented in a case-control association study of schizophrenia. "
11/01/2006 - "There are practically no clinical studies of long-term treatment of schizophrenia and CYP2D6 polymorphism. "
06/01/2005 - "In this study we have investigated the significance of CYP3A4*1B and CYP2D6*4 polymorphisms in TD susceptibility among chronic schizophrenia patients (n = 335) from north India. "
|2.||Cytochrome P-450 CYP2D6 (CYP2D6)
|9.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|2.||Drug Therapy (Chemotherapy)
|5.||Cesarean Section (Caesarean Section)